Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


TRANSGENE BIOTEK LTD.

TRANSGENE BIOTEK LTD. Patent applications
Patent application numberTitlePublished
20120027763Antibody for Targeted induction of Apoptosis, CDC and ADCC mediated killing of Cancer cells, TBL-CLN1 - Antibody for targeted induction of Apoptosis, CDC and ADCC mediated killing of Cancer cells, TBL-CLN1, is disclosed. The antibodies, TBL-CLN1, are monoclonal antibodies which can specifically target and bind to the epitope of SEQ ID NO:1 expressed on cancer cells which further leads to killing of cancer cells. TBL-CLN1 is not conjugated to toxin or cytotoxic molecules, and provides selective killing of cancer cells just by binding to cancer cell surface. Also, disclosed herein is SEQ ID NO: 2 which is an engineered epitope which comprises of polypeptide sequence of SEQ ID NO: 1 and a cysteine residue which is added at the carboxyl end of the SEQ ID NO: 1. The epitope of SEQ ID NO: 2 is used to generate monoclonal antibodies described herein.02-02-2012